vs
AdvanSix Inc.（ASIX）与LifeStance Health Group, Inc.（LFST）财务数据对比。点击上方公司名可切换其他公司
LifeStance Health Group, Inc.的季度营收约是AdvanSix Inc.的1.1倍（$382.2M vs $359.9M），LifeStance Health Group, Inc.净利率更高（3.1% vs -0.8%，领先3.8%），LifeStance Health Group, Inc.同比增速更快（17.4% vs 9.4%），LifeStance Health Group, Inc.自由现金流更多（$46.6M vs $36.1M），过去两年LifeStance Health Group, Inc.的营收复合增速更高（12.8% vs 3.4%）
AdvanSix Inc.是一家美国化工企业，主营尼龙6以及己内酰胺、硫酸铵肥料等相关化工产品。该公司原为霍尼韦尔旗下树脂与化工事业部，于2016年分拆独立，2019年预估营收达14亿美元，其企业历史可追溯至1884年在宾夕法尼亚州法兰克福成立的H. W. Jayne公司。
LifeStance Health Group是美国的门诊行为健康服务提供商，支持线下面诊与远程诊疗两种服务模式，业务涵盖心理咨询、精神科诊疗、经颅磁刺激（TMS）以及氯胺酮治疗等。该公司曾多次因劳动违规、客户信息泄露及误导投资者相关问题遭遇诉讼。
ASIX vs LFST — 直观对比
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $359.9M | $382.2M |
| 净利润 | $-2.8M | $11.7M |
| 毛利率 | 7.6% | — |
| 营业利润率 | -0.7% | 4.7% |
| 净利率 | -0.8% | 3.1% |
| 营收同比 | 9.4% | 17.4% |
| 净利润同比 | -892.9% | 264.1% |
| 每股收益（稀释后） | $-0.11 | — |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
| Q4 25 | $359.9M | $382.2M | ||
| Q3 25 | $374.5M | $363.8M | ||
| Q2 25 | $410.0M | $345.3M | ||
| Q1 25 | $377.8M | $333.0M | ||
| Q4 24 | $329.1M | $325.5M | ||
| Q3 24 | $398.2M | $312.7M | ||
| Q2 24 | $453.5M | $312.3M | ||
| Q1 24 | $336.8M | $300.4M |
| Q4 25 | $-2.8M | $11.7M | ||
| Q3 25 | $-2.6M | $1.1M | ||
| Q2 25 | $31.4M | $-3.8M | ||
| Q1 25 | $23.3M | $709.0K | ||
| Q4 24 | $352.0K | $-7.1M | ||
| Q3 24 | $22.3M | $-6.0M | ||
| Q2 24 | $38.9M | $-23.3M | ||
| Q1 24 | $-17.4M | $-21.1M |
| Q4 25 | 7.6% | — | ||
| Q3 25 | 6.8% | — | ||
| Q2 25 | 14.3% | — | ||
| Q1 25 | 14.2% | — | ||
| Q4 24 | 3.4% | — | ||
| Q3 24 | 14.4% | — | ||
| Q2 24 | 17.9% | — | ||
| Q1 24 | 0.9% | — |
| Q4 25 | -0.7% | 4.7% | ||
| Q3 25 | -0.9% | 2.0% | ||
| Q2 25 | 7.7% | -0.9% | ||
| Q1 25 | 7.7% | 0.5% | ||
| Q4 24 | -3.9% | 0.3% | ||
| Q3 24 | 7.5% | 0.0% | ||
| Q2 24 | 11.5% | -5.1% | ||
| Q1 24 | -7.0% | -5.6% |
| Q4 25 | -0.8% | 3.1% | ||
| Q3 25 | -0.7% | 0.3% | ||
| Q2 25 | 7.7% | -1.1% | ||
| Q1 25 | 6.2% | 0.2% | ||
| Q4 24 | 0.1% | -2.2% | ||
| Q3 24 | 5.6% | -1.9% | ||
| Q2 24 | 8.6% | -7.5% | ||
| Q1 24 | -5.2% | -7.0% |
| Q4 25 | $-0.11 | — | ||
| Q3 25 | $-0.10 | — | ||
| Q2 25 | $1.15 | — | ||
| Q1 25 | $0.86 | — | ||
| Q4 24 | $0.02 | — | ||
| Q3 24 | $0.82 | — | ||
| Q2 24 | $1.43 | — | ||
| Q1 24 | $-0.65 | — |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $19.8M | $248.6M |
| 总债务越低越好 | — | $282.8M |
| 股东权益账面价值 | $815.2M | $1.5B |
| 总资产 | $1.7B | $2.2B |
| 负债/权益比越低杠杆越低 | — | 0.19× |
8季度趋势，按日历期对齐
| Q4 25 | $19.8M | $248.6M | ||
| Q3 25 | $23.7M | $203.9M | ||
| Q2 25 | $18.4M | $188.9M | ||
| Q1 25 | $8.3M | $134.3M | ||
| Q4 24 | $19.6M | $154.6M | ||
| Q3 24 | $17.3M | $102.6M | ||
| Q2 24 | $12.1M | $87.0M | ||
| Q1 24 | $20.6M | $49.5M |
| Q4 25 | — | $282.8M | ||
| Q3 25 | — | $284.6M | ||
| Q2 25 | — | $286.4M | ||
| Q1 25 | — | $288.2M | ||
| Q4 24 | — | $290.0M | ||
| Q3 24 | — | $287.3M | ||
| Q2 24 | — | $288.0M | ||
| Q1 24 | — | $288.8M |
| Q4 25 | $815.2M | $1.5B | ||
| Q3 25 | $818.2M | $1.5B | ||
| Q2 25 | $823.7M | $1.5B | ||
| Q1 25 | $794.4M | $1.5B | ||
| Q4 24 | $774.6M | $1.4B | ||
| Q3 24 | $766.4M | $1.4B | ||
| Q2 24 | $746.6M | $1.4B | ||
| Q1 24 | $713.2M | $1.4B |
| Q4 25 | $1.7B | $2.2B | ||
| Q3 25 | $1.7B | $2.1B | ||
| Q2 25 | $1.6B | $2.1B | ||
| Q1 25 | $1.6B | $2.1B | ||
| Q4 24 | $1.6B | $2.1B | ||
| Q3 24 | $1.5B | $2.1B | ||
| Q2 24 | $1.5B | $2.1B | ||
| Q1 24 | $1.5B | $2.1B |
| Q4 25 | — | 0.19× | ||
| Q3 25 | — | 0.19× | ||
| Q2 25 | — | 0.19× | ||
| Q1 25 | — | 0.20× | ||
| Q4 24 | — | 0.20× | ||
| Q3 24 | — | 0.20× | ||
| Q2 24 | — | 0.20× | ||
| Q1 24 | — | 0.20× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $63.7M | $57.6M |
| 自由现金流经营现金流 - 资本支出 | $36.1M | $46.6M |
| 自由现金流率自由现金流/营收 | 10.0% | 12.2% |
| 资本支出强度资本支出/营收 | 7.7% | 2.9% |
| 现金转化率经营现金流/净利润 | — | 4.93× |
| 过去12个月自由现金流最近4个季度 | $6.4M | $110.0M |
8季度趋势，按日历期对齐
| Q4 25 | $63.7M | $57.6M | ||
| Q3 25 | $26.6M | $27.3M | ||
| Q2 25 | $21.1M | $64.4M | ||
| Q1 25 | $11.4M | $-3.1M | ||
| Q4 24 | $64.2M | $62.3M | ||
| Q3 24 | $57.3M | $22.7M | ||
| Q2 24 | $50.2M | $44.1M | ||
| Q1 24 | $-36.2M | $-21.8M |
| Q4 25 | $36.1M | $46.6M | ||
| Q3 25 | $66.0K | $17.0M | ||
| Q2 25 | $-7.2M | $56.6M | ||
| Q1 25 | $-22.6M | $-10.3M | ||
| Q4 24 | $29.8M | $56.0M | ||
| Q3 24 | $26.8M | $17.7M | ||
| Q2 24 | $16.7M | $39.0M | ||
| Q1 24 | $-71.6M | $-26.9M |
| Q4 25 | 10.0% | 12.2% | ||
| Q3 25 | 0.0% | 4.7% | ||
| Q2 25 | -1.7% | 16.4% | ||
| Q1 25 | -6.0% | -3.1% | ||
| Q4 24 | 9.1% | 17.2% | ||
| Q3 24 | 6.7% | 5.7% | ||
| Q2 24 | 3.7% | 12.5% | ||
| Q1 24 | -21.3% | -9.0% |
| Q4 25 | 7.7% | 2.9% | ||
| Q3 25 | 7.1% | 2.8% | ||
| Q2 25 | 6.9% | 2.2% | ||
| Q1 25 | 9.0% | 2.2% | ||
| Q4 24 | 10.4% | 1.9% | ||
| Q3 24 | 7.7% | 1.6% | ||
| Q2 24 | 7.4% | 1.6% | ||
| Q1 24 | 10.5% | 1.7% |
| Q4 25 | — | 4.93× | ||
| Q3 25 | — | 25.34× | ||
| Q2 25 | 0.67× | — | ||
| Q1 25 | 0.49× | -4.36× | ||
| Q4 24 | 182.29× | — | ||
| Q3 24 | 2.57× | — | ||
| Q2 24 | 1.29× | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ASIX
| Plant Nutrients | $140.0M | 39% |
| Chemical Intermediates | $92.8M | 26% |
| Caprolactam | $64.4M | 18% |
| Nylon Resins | $62.8M | 17% |
LFST
暂无分部数据
